Strategic partnerships

In the first quarter of 2020, Revance entered into a distribution agreement with TEOXANE SA making Revance the exclusive commercialization partner of the company’s innovative Teoxane RHA® Collection – resilient hyaluronic acid. Under the distribution agreement, Revance gained immediate and exclusive rights to commercialize the Teoxane RHA® Collection of dermal fillers in the U.S., including the FDA-approved RHA Redensity®, RHA® 2, RHA® 3, and RHA® 4. The agreement also includes an ongoing collaboration with TEOXANE SA for a robust pipeline of additional indications and next-generation dermal filler technologies.

In partnership with Viatris Inc. (formerly known as Mylan N.V.), Revance is developing a biosimilar to BOTOX®, which would allow our product to compete in the existing short-acting neuromodulator marketplace, while focusing commercial efforts on creating a new neuromodulator category.

BOTOX® is a registered trademark of Allergan, Inc.